Building on the Pfizer 17-year history in Missouri, a newly opened, US$236 million, 295,000 square feet facility in Chesterfield will expand the capacity of colleagues dedicated to the research and development of potential medicines and vaccines.
The new campus will employ over 600 people, bringing more than 80 new STEM positions to the area.
New state-of-the-art features of the campus include:
- A floor plan which provides flexible laboratory layouts
- Scientific casework and utility hookups
- Open office and collaboration spaces
- Increased conferencing technologies where researchers can collaborate, and
- Large open spaces – cafeteria, courtyard, common areas, and more – with natural lighting and exterior views in labs and offices
Chesterfield colleagues, who are a part of Pfizer’s BioTherapeutics Pharmaceutical Sciences organization, specialize in developing products and product candidates for vaccines, rare diseases and genetic medicines, oncology, inflammation and immunology, as well as internal medicine.
One colleague, Adekunle Olatunbosun Onadipe, an Associate Research Fellow in the Bioprocess Research and Development group, has a unique role. He leads the search for the ‘best cell’ among the many cells that are made in our Missouri lab. “We are looking for sustained performance, a ‘seasoned rockstar,’ not a “one hit wonder,” says Adekunle.